Diagnostic Screening and Therapeutic Updates in Morphea, Eosinophilic Fasciitis, and Systemic Sclerosis

Conclusions

• For deep active morphea, disease activity remains difficult to assess clinically, but MRI, color Doppler ultrasound, and multispectral imaging appear more promising than current blood biomarkers.
• CXCL9 is unlikely to become a broadly useful morphea biomarker because it overlaps too much with healthy controls and poorly predicts flares.
• For active deep morphea, steroids plus methotrexate remain first-line, with MMF or abatacept as next options and IVIG, JAK inhibitors, or tocilizumab as emerging rescue therapies.
• Superficial morphea is still best managed with topical corticosteroids, tacrolimus or calcipotriene, and phototherapy.
• Burned-out morphea is shifting toward reconstructive or cosmetic interventions such as fat transfer, microneedling, and fractionated CO2 laser, but evidence is still limited.
• In eosinophilic fasciitis, MRI can often replace morbid fascial biopsy because imaging sensitivity is high and only slightly below biopsy in published series.
• PET-CT performs poorly for eosinophilic fasciitis and should not be used routinely to make the diagnosis.
• Eosinophilic fasciitis diagnosis should rely on the characteristic exam, historical or current eosinophilia, hypergammaglobulinemia, MRI fascial involvement, and exclusion of systemic sclerosis.
• Eosinophilic fasciitis is associated with malignancy, especially hematologic disease, so cancer screening and follow-up of CBC abnormalities are warranted.
• Eosinophilic fasciitis treatment is still largely case-series based, but early high-dose steroids with a DMARD such as methotrexate are the preferred approach, with MMF or IVIG for refractory disease.
• In systemic sclerosis, pattern of skin involvement helps predict autoantibodies, systemic complications, and likely prognosis.
• Very early systemic sclerosis can be identified by the combination of Raynaud phenomenon, puffy hands, positive ANA, and either SSc-specific antibodies or nailfold capillary abnormalities.
• For systemic sclerosis skin disease, mycophenolate mofetil is often favored in practice over methotrexate because of lung toxicity concerns, with rituximab and then IVIG as later options.
• Newer trial data suggest several targeted agents, including romilkimab, riociguat, and ziritaxestat, may improve skin scores and deserve further study.
• CAR T-cell therapy is emerging as a potentially transformative treatment for refractory systemic sclerosis, with early reports showing sustained improvements in lung function, skin scores, and remission off therapy.
• CAR-NK therapy is another promising cellular approach that may reduce some risks of CAR T therapy while still producing clinical improvement in systemic sclerosis.
• Symptom-directed vascular and calcium-deposition complications of systemic sclerosis remain difficult to treat, with lasers helping telangiectasias and calcinosis still requiring individualized, often low-evidence interventions.